Apellis Pharmaceuticals Inc., of Waltham, Mass., closed its public offering of 6.9 million shares, including 900,000 shares to fulfill the underwriters' option to purchase additional shares, at $17 per share, which grossed the company $117.3 million. Citigroup, J.P. Morgan and Cowen acted as joint book-running managers for the offering. Cantor Fitzgerald & Co. acted as lead manager for the offering.